Alanine Transaminase: Why Your ALT Level Might Be Lying About Your Liver

The Normal Range Is Probably Wrong

A study of over 272,000 people found that when you exclude everyone with metabolic risk factors (high blood sugar, elevated cholesterol, obesity), the 95th percentile for ALT drops to 37.5 U/L, far below the 52 U/L cutoff that many labs still use. That means roughly 1 in 16 people whose ALT falls under the manufacturer's threshold actually exceed what a truly healthy population looks like.

The U.S. National Health and Nutrition Examination Survey pushed this even further. Using over 4,000 adults, researchers found that the ALT values that best distinguished people with hepatitis C from those at low risk of liver disease were 29 U/L for men and 22 U/L for women. At those thresholds, the test caught about 88-89% of confirmed infections with roughly 82-83% specificity.

A separate analysis of over 7,000 blood donors proposed similar numbers, recommending lower healthy ranges particularly for screening patients with chronic hepatitis C or nonalcoholic fatty liver disease.

The pattern holds in children too. A study of nearly 1,000 school-age kids established upper limits of 30 U/L for boys and 21 U/L for girls, after excluding those with metabolic risk factors.

Why haven't labs caught up? Partly because reference ranges are expensive and slow to update, and partly because lowering the cutoff means flagging millions of additional patients as abnormal. That creates downstream workload. But from a detection standpoint, the evidence is consistent: the current "normal" is too generous.

What's Actually Pushing ALT Up

Fatty liver disease is now the single most common reason for elevated ALT in the general population. In a community screening study of over 3,200 adults, nonalcoholic fatty liver disease (NAFLD, now called MASLD) was the single most common cause, accounting for about 34% of all elevated ALT cases, ahead of hepatitis B (29%) and hepatitis C (13%) individually. A separate population study in Iran confirmed NAFLD as the leading cause of persistently elevated ALT.

But NAFLD is only part of the picture. The metabolic factors that drive fatty liver also independently raise ALT. In a study of over 26,000 people, ALT levels among those with NAFLD climbed in a dose-response pattern with each additional component of metabolic syndrome: larger waist circumference, higher triglycerides, elevated fasting glucose, and higher blood pressure all independently predicted higher ALT.

Here is what makes this tricky: ALT is not perfectly liver-specific. The enzyme exists in two forms. ALT1 is found in the intestine, liver, fat tissue, colon, muscle, and heart. ALT2 is mainly in the liver, muscle, and brain.

So a bump in ALT could theoretically come from muscle injury, not liver damage. This is why context matters when interpreting a result, especially in someone who exercises intensely.

Medications can also nudge ALT upward without causing meaningful liver harm. Certain common drugs, including statins and some pain relievers, are known to cause transient ALT elevations that don't necessarily indicate toxicity.

ALT Within Normal Range Can Still Signal Trouble

This is where the research gets uncomfortable. A prospective study of over 5,200 healthy, nondiabetic men found that ALT levels within the normal reference range still predicted who would develop fatty liver disease over the next four years. Compared to men with ALT below 16 U/L, those with ALT between 26 and 34 U/L (still technically "normal") had more than double the risk of developing NAFLD, even after adjusting for BMI, insulin resistance, blood pressure, and other confounders.

That finding holds even in normal-weight individuals who maintained normal liver enzymes throughout the follow-up period. In other words, a "normal" ALT in the upper half of the range was an early warning sign that the liver was already accumulating fat.

On the flip side, a normal ALT doesn't guarantee the liver is fine. Among 222 biopsy-proven NAFLD patients, 37.5% of those with normal ALT had either NASH (the inflammatory form of fatty liver) or advanced fibrosis. Meanwhile, 53% of those with elevated ALT turned out to have neither.

The 20-Year Metabolic Risk

ALT's predictive power extends well beyond the liver. The Framingham Offspring Heart Study followed 2,812 people for 20 years and found that each standard-deviation increase in log ALT was associated with 21% higher odds of developing metabolic syndrome and 48% higher odds of developing diabetes. These associations held even among people whose ALT levels were within the normal range at baseline.

Another prospective study of 633 people tracked over about five years found that those in the top quartile of ALT had 2.5 times the odds of developing metabolic syndrome compared to those in the bottom quartile, even after accounting for waist circumference and directly measured insulin sensitivity.

The metabolic syndrome connection matters because MASLD is increasingly understood as a systemic condition, not just a liver problem. A 2024 systematic review documented that 50-80% of MASLD patients have other metabolic conditions like type 2 diabetes, dyslipidemia, and hypertension.

More than 90% of obese patients with type 2 diabetes have the inflammatory form of fatty liver disease. And in middle-aged adults, MASLD independently raises the risk of cardiovascular mortality, sarcopenia, and chronic kidney disease.

So an ALT level that looks benign on a standard lab report might be the earliest detectable clue that a metabolic cascade is underway.

What ALT Can and Cannot Tell You

ALT is excellent at one specific job: flagging acute liver cell injury. When hepatocytes are damaged, whether by a virus, a drug reaction, or toxic exposure, ALT pours into the bloodstream and the number spikes dramatically. For this purpose, the enzyme remains one of the most sensitive markers available.

Where ALT falls short is in the chronic, slow-burn conditions that affect far more people. It can miss cirrhosis because by the time scar tissue replaces liver cells, there may not be enough healthy hepatocytes left to release much ALT. It can miss NASH because inflammation and fibrosis don't always produce proportional enzyme elevations.

Elevated GGT (gamma-glutamyltransferase) may actually be a stronger signal for broader health risk. In a study of nearly 15,000 U.S. adults followed for 12 years, elevated GGT was associated with increased mortality from all causes, liver disease, cancer, and diabetes. Elevated ALT, by contrast, was only associated with liver disease mortality. This suggests that while ALT is a useful liver-specific alarm, GGT captures more of the systemic metabolic damage that ultimately drives outcomes.

The AST-to-ALT ratio adds another diagnostic layer. A higher AST-to-ALT ratio has been associated with reduced risk of metabolic syndrome, while a lower ratio (where ALT dominates) is an independent predictor of metabolic syndrome development.

What to Do About a Borderline Result

If your ALT is in the upper half of the "normal" range, say above 25 U/L for women or above 30 U/L for men, the research suggests it deserves attention rather than dismissal. A Liver Function Panel through Instalab ($8, no referral needed) gives you a more complete picture by measuring ALT alongside AST, alkaline phosphatase, bilirubin, and albumin, which together reveal whether the liver is inflamed, struggling to clear waste, or losing its ability to make essential proteins.

Because NAFLD is the top driver of elevated ALT, and because fat in the liver responds to caloric reduction, weight loss may help improve liver enzyme levels. Exercise may also help, likely through its impact on insulin resistance and body composition.

For anyone with persistent ALT elevation, the research points to evaluating the full metabolic picture: fasting glucose, triglycerides, waist circumference, and blood pressure. ALT in isolation is a clue. Combined with metabolic context, it becomes a much more informative signal about where your health is headed over the next decade or two.